The Liver and Its Metabolic Functions

The liver is the largest internal organ, weighing about 1.5 kg in an adult, and it is anatomically positioned as a gatekeeper between the gut and the systemic circulation. Roughly 70–75% of its blood supply arrives via the hepatic portal vein, carrying everything absorbed by the small intestine — monosaccharides, amino acids, short- and medium-chain fatty acids, and many ingested drugs and toxins — directly to hepatocytes before that blood ever reaches the heart. The remaining 25–30% arrives via the hepatic artery, supplying oxygen. Both streams drain into the same sinusoids and exit through the hepatic vein into the inferior vena cava. This "first-pass" arrangement means the liver can extract, store, or chemically modify nutrients and xenobiotics before they are seen by any other organ, a principle clinically important for oral drug bioavailability (first-pass metabolism). Functionally, the liver runs a set of interconverting metabolic pathways rather than a single fixed process. In the fed (absorptive) state, driven by high insulin and low glucagon, hepatocytes take up glucose and convert it to glycogen (glycogenesis) and, when glycogen stores are full, to fatty acids (lipogenesis) packaged into very-low-density lipoprotein (VLDL) for export. In the fasted (postabsorptive) state, low insulin and rising glucagon reverse this: glycogen is broken down (glycogenolysis) and, once glycogen is depleted (roughly 12–18 hours into a fast), the liver synthesizes new glucose from lactate, glycerol, and amino acids (gluconeogenesis) and increasingly oxidizes fatty acids to produce ketone bodies (ketogenesis) that spare glucose for the brain. This fed–fasted toggle is the liver's signature behavior and the reason it is often called the body's "glucose buffer" or "metabolic thermostat." Beyond fuel handling, the liver performs three other jobs central to whole-body physiology: it synthesizes nearly all circulating plasma proteins (albumin, fibrinogen, prothrombin, and other clotting factors, and transport proteins), it produces bile continuously for fat digestion and cholesterol/bilirubin excretion, and it detoxifies endogenous waste (ammonia, via the urea cycle) and exogenous compounds (drugs, alcohol, environmental toxins) via oxidative and conjugative enzyme systems. These functions are carried out by the same hepatocyte population, organized into repeating structural units called lobules, with blood flowing from the portal triads at the lobule periphery inward to a central vein — a geometry that creates metabolic "zonation," discussed below.

Hepatic architecture and blood flow. The functional unit of the liver is the lobule: a roughly hexagonal arrangement of hepatocyte plates radiating around a central vein, with portal triads (a branch of the hepatic artery, a branch of the portal vein, and a bile duct) at each of the six corners. Blood from the artery and portal vein mixes and percolates through fenestrated capillaries called sinusoids, flowing from the portal triads toward the central vein; bile flows in the opposite direction, from hepatocytes into bile canaliculi and toward the bile ducts at the periphery. Because blood is progressively depleted of oxygen and nutrients as it flows toward the central vein, hepatocytes near the portal triad ("zone 1," periportal) are relatively oxygen-rich and specialize in oxidative processes — gluconeogenesis, fatty acid oxidation, and the initial steps of the urea cycle — while hepatocytes near the central vein ("zone 3," pericentral) are relatively oxygen-poor and specialize in glycolysis, lipogenesis, and glutamine synthesis, and are also where cytochrome P450 detoxification is concentrated (and where alcohol- or drug-induced injury often centers, because toxic metabolites are generated there under lower oxygen tension).

Carbohydrate handling. After a meal, portal blood glucose rises sharply. Hepatocytes take up glucose via the GLUT2 transporter (a high-capacity, low-affinity transporter that lets glucose flow according to concentration rather than being tightly rate-limited), and rising insulin activates glucokinase, trapping glucose as glucose-6-phosphate. This feeds glycogen synthase (activated when insulin dephosphorylates it) to build glycogen chains, which can reach roughly 100 g of stored glycogen in a well-fed adult liver (compared with ~400 g in skeletal muscle, though muscle glycogen cannot be released as blood glucose because muscle lacks glucose-6-phosphatase). Between meals, falling insulin and rising glucagon activate glycogen phosphorylase via a cAMP–protein kinase A cascade, releasing glucose-1-phosphate, which is converted to glucose-6-phosphate and then, uniquely in liver (and kidney), dephosphorylated by glucose-6-phosphatase to free glucose that can cross the hepatocyte membrane back into blood. Once glycogen is exhausted, gluconeogenesis takes over, using lactate (from muscle and red blood cells, via the Cori cycle), glycerol (from adipose lipolysis), and glucogenic amino acids (from muscle proteolysis, principally alanine) as carbon sources, essentially running glycolysis in reverse with three energy-requiring bypass steps.

Lipid handling. Dietary and endogenously synthesized fatty acids entering the liver are re-esterified into triglycerides and combined with apolipoproteins (chiefly apoB-100), phospholipids, and cholesterol to form VLDL particles, which are secreted into blood and deliver triglycerides to adipose and muscle via lipoprotein lipase. When fasting is prolonged, fatty acids released from adipose tissue arrive at the liver and are oxidized in mitochondria via β-oxidation; the resulting acetyl-CoA, in excess of what the tricarboxylic acid cycle can accommodate (because oxaloacetate is diverted into gluconeogenesis), is instead converted into the ketone bodies acetoacetate and β-hydroxybutyrate. These are released into blood and used by extrahepatic tissues, notably brain after several days of starvation, as a glucose-sparing fuel — hepatocytes themselves lack the enzyme (thiophorase/succinyl-CoA transferase) needed to reutilize ketones.

Protein handling and the urea cycle. Amino acids absorbed in excess of immediate protein-synthetic needs are deaminated; the amino group is removed as ammonia (NH₃), which is toxic to the central nervous system at even modest concentrations. Hepatocytes (again predominantly periportal ones) convert ammonia into urea via the urea cycle: ammonia and CO₂ combine (with two ATP) to form carbamoyl phosphate, which combines with ornithine to eventually yield arginine, which is cleaved by arginase to release urea and regenerate ornithine. Urea is water-soluble, non-toxic, and excreted by the kidneys — a mechanism absolutely essential to nitrogen balance, since dietary protein turnover generates the equivalent of tens of grams of nitrogen waste daily.

Bile production. Hepatocytes continuously secrete bile — containing bile acids (synthesized from cholesterol), bilirubin (from heme breakdown), cholesterol, phospholipids, and electrolytes — into canaliculi that merge into bile ducts and ultimately the common bile duct. Between meals, bile is diverted into the gallbladder, where it is concentrated up to tenfold by active NaCl reabsorption (water follows osmotically). Cholecystokinin, released by the duodenum in response to fat and protein, triggers gallbladder contraction and relaxation of the sphincter of Oddi, delivering a bolus of bile into the duodenum. Bile acids emulsify large fat globules into micelles, vastly increasing surface area for pancreatic lipase — a direct continuation of the absorptive machinery this article's prerequisite covers. About 95% of bile acids are reabsorbed in the terminal ileum and returned to the liver via the portal vein (enterohepatic circulation), recycled roughly 6–10 times per meal cycle before excretion in feces.

Detoxification. Hepatocyte smooth endoplasmic reticulum contains cytochrome P450 enzyme families that carry out phase I reactions (oxidation, reduction, hydrolysis), typically making a compound more polar and sometimes exposing a reactive group; phase II reactions then conjugate that group with glucuronic acid, sulfate, glycine, or glutathione, rendering the compound water-soluble enough for excretion in bile or urine. This system handles both endogenous molecules (steroid hormones, bilirubin) and exogenous ones (ethanol, many prescription drugs), and its capacity can be induced (e.g., chronic alcohol use upregulates CYP2E1, which is also how tolerance and increased acetaminophen toxicity arise together) or saturated (explaining why alcohol and certain drugs compete for the same enzymes, altering each other's clearance).

Claude Bernard and hepatic glycogen (1850s–1857). Before the liver's buffering role was understood, physiologists assumed sugar in blood came directly and only from digested dietary carbohydrate. Claude Bernard tested this by feeding dogs a meat-only, carbohydrate-free diet and then measuring blood leaving versus entering the liver. He found glucose in the hepatic vein blood even though the animals had eaten no sugar, and even when the liver was tested in isolation after death. Bernard concluded the liver itself manufactures and stores a sugar-yielding substance, which he named "glycogène" (1857), and that the liver releases glucose into blood independent of immediate dietary intake. This was a landmark demonstration of an internal secretion regulating blood chemistry — one of the conceptual foundations of endocrinology and homeostasis — and directly established the liver's role as a glucose reservoir, later shown to be mobilized by glycogen phosphorylase under hormonal control (Carl and Gerty Cori's later biochemical work on glycogen phosphorylase, 1930s–40s, elucidated the enzymatic mechanism Bernard's physiology had implied).

Hans Krebs and Kurt Henseleit: the urea cycle (1932). Before 1932, it was known that liver tissue could convert ammonia to urea, but no pathway had been described — indeed, no cyclic metabolic pathway of any kind had yet been demonstrated in biochemistry. Krebs and Henseleit, working with thin slices of rat liver suspended in buffered saline (a technique allowing them to measure metabolite production quantitatively), added ammonium salts together with various candidate intermediates and measured urea output manometrically and chemically. They found that adding ornithine caused a huge, catalytic increase in urea production — far more urea was produced than could be accounted for stoichiometrically by the ornithine added, meaning ornithine was being regenerated and reused. Adding citrulline or arginine similarly stimulated urea production. From these quantitative relationships (small amounts of ornithine causing production of urea far in excess of the ornithine supplied) they correctly inferred a cyclic pathway: ornithine → citrulline → arginine → urea + regenerated ornithine. This was the first metabolic cycle described in biochemistry, predating and directly inspiring Krebs's own later discovery of the citric acid cycle (1937). It remains a textbook example of using stoichiometric mismatch (catalytic amplification) as evidence for cyclic rather than linear pathways.

Isotope tracer studies confirming gluconeogenesis (mid-20th century). Using radiolabeled lactate and amino acids infused into fasted animals, researchers (building on the Cori cycle work of Carl and Gerty Cori, who received the Nobel Prize in 1947 for glycogen and carbohydrate metabolism studies) demonstrated that labeled carbon from muscle-derived lactate appeared in newly synthesized liver glycogen and blood glucose, confirming that the liver runs glycolysis in reverse using peripheral substrates during fasting — directly validating the fed/fasted switching model described above.

Example 1 — how long do liver glycogen stores actually last? An adult liver stores approximately 100 g of glycogen when fully fed. The brain alone consumes glucose at roughly 5–6 g per hour at rest (≈120 g/day), and other tissues (red blood cells, renal medulla, some muscle) add further obligate glucose demand, bringing whole-body glucose utilization in the fasted state to roughly 8 g/hour overall once tissues shift substrate preference somewhat toward fat. Given:

• Liver glycogen store ≈ 100 g glucose-equivalent
• Basal whole-body glucose utilization in early fasting ≈ 8 g/hour (before ketone/fatty-acid substitution ramps up)

Calculation: 100 g ÷ 8 g/hour ≈ 12–13 hours This is why blood glucose starts to depend increasingly on gluconeogenesis after roughly half a day of fasting — matching the clinical teaching that an overnight fast (~12 hours) is right at the point where glycogenolysis alone is becoming insufficient and gluconeogenesis is ramping up, which is exactly why a "fasting glucose" test is standardized at 8–12 hours: long enough to clear the last meal's absorptive glucose, short enough that gluconeogenic compensation hasn't introduced its own variability from severe starvation physiology.

Example 2 — interpreting deranged liver function tests in a clinical scenario. A patient with chronic heavy alcohol use presents with the following labs (reference ranges in parentheses):

• Serum albumin: 2.4 g/dL (normal 3.5–5.0 g/dL)
• Prothrombin time (PT): markedly prolonged
• Serum ammonia: elevated
• Blood glucose: 58 mg/dL (mildly low) after an overnight fast
• Serum bilirubin: elevated, with jaundice on exam

Reasoning through the mechanism, not just pattern-matching: 1. Low albumin — albumin is synthesized exclusively by hepatocytes and has a plasma half-life of about 20 days; a low level in this context reflects chronic reduced synthetic capacity (not, e.g., acute dietary protein deficiency, which would take weeks to manifest and wouldn't explain the other findings together). 2. Prolonged PT — most clotting factors (I, II, V, VII, IX, X) are hepatic products; because several have short half-lives (factor VII, ~6 hours), PT is a more sensitive and rapid indicator of synthetic liver failure than albumin. 3. Elevated ammonia — the urea cycle, run in periportal hepatocytes, is failing to clear the nitrogen load from protein catabolism and gut bacterial activity; this ammonia can cross the blood–brain barrier and contribute to hepatic encephalopathy (confusion, asterixis), explaining a plausible altered-mental-status component of this presentation. 4. Mild fasting hypoglycemia — with damaged hepatocytes, both glycogen storage capacity and gluconeogenic enzyme function (many gluconeogenic enzymes are themselves hepatic proteins requiring intact synthetic machinery) are impaired, so the normal 12+ hour fasting buffer is shortened. 5. Jaundice/elevated bilirubin — damaged hepatocytes are less able to conjugate and excrete bilirubin from heme breakdown into bile, and canalicular/bile duct disruption from cirrhotic architecture further impairs excretion, producing the yellow discoloration. This constellation — low albumin, prolonged PT, hyperammonemia, hypoglycemia tendency, and hyperbilirubinemia — is not five unrelated findings but one lesion (widespread hepatocyte loss/dysfunction) manifesting through five distinct normal liver functions failing simultaneously, which is exactly why liver function panels are read as a set rather than individually.

Hans Krebs trained as a physician in Germany and worked in Otto Warburg's laboratory in Berlin, where he learned the manometric tissue-slice techniques (measuring gas exchange of living tissue slices to infer metabolic reactions) that he would later apply independently. Dismissed from his academic position in 1933 under Nazi racial laws because he was Jewish, Krebs emigrated to England, where he continued his research at Cambridge and then Sheffield. His meticulous, quantitative style — insisting that proposed metabolic intermediates be tested by adding them to tissue preparations and measuring whether they catalytically accelerated the reaction, rather than simply being consumed stoichiometrically — became the methodological signature of his career and is exactly what let him and Kurt Henseleit correctly infer a cyclic rather than linear pathway for urea synthesis in 1932, and later the citric acid cycle in 1937.

Hepatology and transplantation medicine. Liver function tests (albumin, PT/INR, bilirubin, transaminases, ammonia) built directly on the mechanisms above are used daily to stage cirrhosis, decide transplant priority (via scores like MELD, which explicitly uses bilirubin, INR, and creatinine), and monitor post-transplant graft function.

Pharmacology and drug development. First-pass hepatic metabolism determines oral drug dosing; cytochrome P450 induction and inhibition (e.g., by grapefruit juice, rifampin, or alcohol) explain major, sometimes dangerous, drug–drug interactions, and are now screened for in every new drug candidate before approval.

Toxicology and emergency medicine. Understanding that acetaminophen toxicity depends on glutathione-dependent phase II detoxification of a phase I metabolite led directly to N-acetylcysteine therapy, which replenishes glutathione and remains the standard antidote for acetaminophen overdose.

Metabolic disease. Non-alcoholic fatty liver disease (NAFLD), now affecting an estimated 25–30% of adults in industrialized countries, results from excess hepatic lipogenesis and impaired VLDL export overwhelming storage capacity, directly implicating the fed-state lipid pathways described here, and is a growing focus of both public health messaging and pharmaceutical development.

Diabetes management. Because the liver's gluconeogenic and glycogenolytic output is a major contributor to fasting hyperglycemia in type 2 diabetes, drugs like metformin work substantially by suppressing hepatic glucose production — a direct therapeutic application of the fed/fasted switching mechanism.

Nutrition and critical care. Total parenteral nutrition protocols and refeeding guidelines for malnourished or critically ill patients are designed around known limits of hepatic glycogen storage and gluconeogenic capacity, preventing complications like refeeding syndrome.

Ask the tutor: How does the liver's handling of glucose and fat change across a 24-hour eating cycle, and how would that pattern be disrupted in someone with insulin resistance?